New cocktail of drugs and radiation takes on tough lung cancer
NCT ID NCT04728230
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of the PARP inhibitor olaparib, the immunotherapy durvalumab, chemotherapy (carboplatin and etoposide), and radiation in people with extensive-stage small cell lung cancer who haven't been treated yet. The goal is to see if this mix is safe and works better than current treatments. About 63 participants will be enrolled at M.D. Anderson Cancer Center.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Olaparib (PARP inhibitor), durvalumab (immunotherapy), carboplatin, etoposide, and radiation therapy
- What this could lead to
- If successful, this combination could become a new standard first-line treatment for extensive-stage small cell lung cancer, potentially improving how long patients live without their cancer growing.
- What could go wrong
- This is an early-phase trial with only 63 participants, so results may not apply to all patients. Combining multiple treatments also raises the risk of serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
- Wheat germ supplement studied for immune boost in advanced cancer
- New drug combo tested for tough lung cancer – modest hopes
- Brain radiation may be skipped in lung cancer: new trial tests safer monitoring
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy